Cerebral vasospasm after subarachnoid hemorrhage (SAH) is a major clinical problem causing cerebral ischemia and infarction. The pathogenesis of vasospasm is related to a number of pathological processes including endothelial damage and alterations in vasomotor function leading to narrowing of arterial diameter and a subsequent decrease in cerebral blood flow. Discovery of the tissue protective effects of erythropoietin (EPO) stimulated the search for therapeutic application of EPO for the prevention and treatment of cerebrovascular disease. Recent studies have identified the role of EPO in vascular protection mediated by the preservation of endothelial cell integrity and stimulation of angiogenesis. In this review, we discuss the EPO-induced activation of endothelial nitric oxide (NO) synthase and its contribution to the prevention of cerebral vasospasm.
Introduction
Erythropoietin (EPO), produced in the fetal liver and adult kidney, is a 165 amino acid (~30 kDa) serum glycoprotein, responsible for the proliferation, survival and differentiation of erythroid progenitor cells. The production and secretion of EPO is oxygen-dependent. Once a hypoxic stimulus is received, EPO is released into the peripheral circulation, and upon arrival in the bone marrow, EPO binds to its receptor on the erythroid progenitor cells and leads to erythropoiesis [1] . In addition, EPO stimulates the proliferation and maturation of erythroid cells [2, 3] .
Tissue protective effects of EPO
The concept that erythropoiesis was the only original principal action of EPO changed with the realization that EPO and its receptor (EPOR) were expressed in the brain, heart, and uterus [1, 4, 5] . In addition to its effect on erythroid progenitor cells, EPO exerts several biological effects on endothelial, vascular smooth muscle, myocardial, mesangial and neuronal cells [6] [7] [8] [9] [10] [11] [12] . The production and secretion of EPO and the expression of EPOR are controlled by tissue oxygen supply and are mainly regulated by hypoxia-inducible factors [13] . In addition to hypoxia, EPO can be upregulated by estrogen, insulin, pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), as well as by EPO itself [14] [15] [16] [17] [18] . The mechanisms of tissue protection by EPO include several different signal transduction pathways. When EPO binds to EPOR, it causes dimerization of the receptor, autophosphorylation of Janus-tyrosine-kinase-2 (JAK-2) and receptor activation. JAK-2 activation leads to several downstream signaling pathways including Ras-mitogen activated protein kinase (MAPK), phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) and the transcription factor signal transducers and activators of transcription-5 (STAT-5; Figure 1) . Additionally, EPO has been shown to modulate intracellular calcium concentrations in excitable cells by activating phospholipase C-γ. Another mechanism that may contribute to the protective role of EPO is the enhancement of antioxidant defense mechanisms. EPO increases the activity of antioxidant enzymes, such as superoxide dismutase, glutathione peroxidase and catalase, and protects the brain against ischemic damage [19, 20] . EPO also seems to modulate the proliferation and differentiation of stem cells and can increase the viability of embryonic cortical neurons, promote cell survival and upregulate the proliferative response of neuronal progenitor cells [21, 22] . In addition, EPO increases the number of endothelial progenitor cells mobilized from the bone marrow [23, 24] . The broad efficacy of EPO observed in experimental models of disease depends on its ability to inhibit apoptosis, restoration of vascular autoregulation, attenuation of inflammatory responses and augmentation of restorative functions, including the direct recruitment of stem cells [25, 26] . Of all the non-hematopoietic biological roles of EPO, the contribution of EPO to neuroprotection has received the most attention. The ability of EPO to penetrate the blood-brain barrier has been pivotal to its application as a neurotherapeutic agent, as intrathecal administration is not practical in most clinical settings [27, 28] . A recent proof-of-concept clinical trial demonstrated beneficial effect of EPO in patients who suffered an acute stroke, and encouraged the evaluation of this cytokine in various models of tissue injury [29] .
Role of nitric oxide (NO) in the cerebral vascular protective effects of EPO
EPO plays a dual role in vascular protection by preserving endothelial cell integrity and by promoting angiogenesis [30] [31] [32] .
In transgenic mice overexpressing human EPO, endothelial NO synthase (eNOS) expression in the arteries increased and was accompanied by enhanced NO-mediated endothelium-dependent relaxation and elevated circulating and vascular tissue NO [33] . The ability of EPO to increase NOS activity in endothelial cells [14, 34] prompted us to investigate the contribution of endothelium-derived NO to the vascular protective effects of EPO.
To study the cerebrovascular effects of EPO, an adenovirus encoding recombinant EPO (AdEPO) was injected intracisternally into rabbits. Forty-eight hours later, the expression of EPO was observed in the basilar arteries. In arteries transduced with AdEPO, the expressions of eNOS and its phosphorylated (S1177) form were increased. Basal levels of cyclic GMP were significantly elevated in the arteries transduced with AdEPO, consistent with increased NO production ( Figure 2 ) [35] . Although, adenovirus-mediated gene transfer into the cisterna magna was performed to increase EPO expression locally in the cerebral arteries, we were able to achieve concentrations of EPO in plasma known to be clinically therapeutic (about 2-5 U/mL), possibly by the crossing of EPO from the cerebrospinal fluid into the circulating blood [27] . In this regard, we wish to point out that the vascular benefits obtained with EPO are most likely dependent on its concentration in the plasma. Although sys- temic administration of EPO (>about 5 times the hematopoietic dose) has been shown to exert tissue protective effects, very high circulating concentrations of EPO (in the range of 20-200 U/mL) exerts vasoconstriction, in part by reducing eNOS expression and/or increasing cytosolic calcium content of vascular smooth muscle cells by the stimulation of protein kinase C and phospholipase Cγ1 [10, [36] [37] [38] [39] . Although the effects obtained with AdEPO were similar to those obtained on transgenic mice overexpressing human EPO [33] , the red blood cells (RBC) number in the arteries transduced with AdEPO were not increased, arguing against the contribution of shear stress in increased NO production.
Cerebral vasospasm after subarachnoid hemorrhage (SAH) leads to high morbidity and mortality of patients affected by ruptured cerebral aneurysms. Demonstrated neuroprotective effects of EPO [40] [41] [42] have been associated with a reduction in vasoconstriction observed in EPO-treated rabbits subjected to SAH. Overexpression of EPO in cerebral arteries reversed vasospasms induced by the injection of autologous blood into the cisterna magna. Arteries transduced with recombinant EPO demonstrated significant augmentation of the endothelium-dependent relaxations to acetylcholine. Transduction with AdEPO further increased the expression of phosphorylated Akt and eNOS and elevated basal levels of cGMP in the spastic arteries ( Figure 3 ) [43] . The neuroprotective effects of EPO obtained in animal models of ischemic brain injury and SAH could be explained in part by the augmented basal production of NO in the endothelium. Furthermore, it is possible that the administration of recombinant EPO reduced the infiltration of mononuclear inflammatory cells after SAH [44, 45] . In cerebral circulation, EPO has a direct action on the endothelium and increases NO bioavailability by the upregulation of eNOS (Figure 4) . Understanding of the multiple tissue protective effects of EPO provides impetus for translation of these findings into the clinical arena. However, the hematopoietic side effects of recombinant EPO, in particular with repeated high doses, have to be avoided to achieve selective tissue protective effects. In such circumstances, the non-hematopoietic analogues of EPO [46, 47] offer a promise of utilizing only the tissue protective benefits of this potent hematopoietic cytokine. 
